참고문헌
- Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219. https://doi.org/10.1136/bmj.326.7382.219
- Brenner B, Shah MA, Karpeh MS et al (2006). A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol, 17, 1404-11. https://doi.org/10.1093/annonc/mdl133
- Coffey DS, Getzenberg RH, DeWeese TL (2006). Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect. JAMA, 296, 445-8. https://doi.org/10.1001/jama.296.4.445
- Deng HJ, Wei ZG, Zhen L et al (2009). Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao, 29, 295-7.
- Ding W, Duan D, Sun G, Gu C (2007). Clinical observation on early intraperitoneal hypertherm ic perfusion chemotherapy in the treatment of stomach carcinoma after operation. Tumor, 27, 585-7.
- Ferlay J, Shin HR, Bray F et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Fujimoto S, Takahashi M, Mutou T et al (1999). Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 85, 529-34. https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9
- Gao Z, Jiang Z, Zhou F (2002). Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang, 29, 294-5.
- Hildebrandt B, Wust P, Ahlers O et al (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol, 43, 33-56. https://doi.org/10.1016/S1040-8428(01)00179-2
- Howell SB, Chu BB, Wung WE et al (1981). Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest, 67, 1161-70. https://doi.org/10.1172/JCI110130
- Kuramoto M, Shimada S, Ikeshima S et al (2009). Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg, 250, 242-6. https://doi.org/10.1097/SLA.0b013e3181b0c80e
- Matharu G, Tucker O, Alderson D (2011). Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg, 98, 1225-35. https://doi.org/10.1002/bjs.7586
- Nakao K, Otsuki Y, Akao Y et al (2000). The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electron Microsc, 33, 44-50. https://doi.org/10.1007/s007950000007
- Newman E, Potmesil M, Ryan T et al (2005). Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol, 32, S97-100. https://doi.org/10.1053/j.seminoncol.2005.06.002
- Ohtsu A, Yoshida S, Saijo N (2006). Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol, 24, 2188-96. https://doi.org/10.1200/JCO.2006.05.9758
- Paoletti X, Oba K, Burzykowski T et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. JAMA, 303, 1729-37. https://doi.org/10.1001/jama.2010.534
- Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
- Ravichandran D, Lamah M, Carty NJ, Johnson CD (1995). Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma. Ann R Coll Surg Engl, 77, 431-6. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
- Roder JD, Bonenkamp JJ, Craven J et al (1995). Lymphadenectomy for gastric cancer in clinical trials: update. World J Surg, 19, 546-53. https://doi.org/10.1007/BF00294718
- Rosen HR, Jatzko G, Repse S et al (1998). Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol, 16, 2733-8. https://doi.org/10.1007/BF00294718
- Roti Roti JL (2008). Cellular responses to hyperthermia (40- 46 degrees C): cell killing and molecular events. Int J Hyperthermia, 24, 3-15. https://doi.org/10.1080/02656730701769841
- Shimoyama S, Shimizu N, Kaminishi M (1999). Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J Surg, 23, 284-91; discussion 91-2. https://doi.org/10.1007/PL00013186
- Speyer JL, Sugarbaker PH, Collins JM et al (1981). Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res, 41, 1916-22. https://doi.org/10.1007/PL00013186
- Takahashi T, Hagiwara A, Shimotsuma M et al (1995). Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg, 19, 565-9. https://doi.org/10.1007/BF00294724
- Tierney JF, Stewart LA, Ghersi D et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
- Wei G, Fang GE, Bi JW et al (2005a). Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng, 24, 478-82. https://doi.org/10.1186/1745-6215-8-16
- Wei G, Fang GE, Bi JW et al (2005b). [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. Ai Zheng, 24, 478-82.
- Yan TD, Black D, Sugarbaker PH et al (2007). A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol, 14, 2702-13. https://doi.org/10.1245/s10434-007-9487-4
- Yang XJ, Huang CQ, Suo T et al (2011). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol, 18, 1575-81. https://doi.org/10.1245/s10434-011-1631-5
- Yonemura Y, de Aretxabala X, Fujimura T et al (2001). Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology, 48, 1776-82. https://doi.org/10.1245/s10434-011-1631-5
- Yu W, Whang I, Chung HY et al (2001). Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg, 25, 985-90. https://doi.org/10.1007/s00268-001-0067-7
- Zhang GY, Chen XC, Pan K et al (2007). Application of hyperthermic intraoperative intraperitoneal chemotherapy in patients with gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 10, 362-4. https://doi.org/10.1007/s00268-001-0067-7
- Zhang W, Su D, WANG K et al (1998). Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi, 27, 67-9.
- Zuo Y, Xu M, Shen D et al (2004). Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhong Liu Za Zhi, 26, 247-9.
피인용 문헌
- Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5231
- Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer vol.2, pp.5, 2014, https://doi.org/10.3892/mco.2014.301
- Peritoneal carcinomatosis of gastrointestinal tumors: Where are we now? vol.20, pp.39, 2014, https://doi.org/10.3748/wjg.v20.i39.14371
- The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art vol.2014, pp.2090-1410, 2014, https://doi.org/10.1155/2014/912418
- miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1171-7
- Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer vol.7, pp.5, 2014, https://doi.org/10.3892/etm.2014.1599
- The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer vol.26, pp.2, 2015, https://doi.org/10.1097/CAD.0000000000000179
- Oral gastrografin radiography for the evaluation of the functional impact of peritoneal carcinomatosis: Correlation with clinicopathological findings vol.3, pp.5, 2015, https://doi.org/10.3892/mco.2015.573
- A Comparison of Intravenous plus Intraperitoneal Chemotherapy with Intravenous Chemotherapy Alone for the Treatment of Gastric Cancer: A Meta-Analysis vol.5, pp.1, 2015, https://doi.org/10.1038/srep12538
- The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer vol.7, pp.2, 2016, https://doi.org/10.1007/s13193-016-0502-8
- Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) vol.7, pp.2, 2016, https://doi.org/10.1007/s13193-016-0497-1
- Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer vol.97, pp.33, 2018, https://doi.org/10.1097/MD.0000000000011949